UROGEN PHARMA (NASDAQ:URGN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Thursday.

According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “

A number of other equities research analysts have also weighed in on URGN. Cowen and Company initiated coverage on shares of UROGEN PHARMA in a report on Tuesday, May 30th. They issued an “outperform” rating on the stock. Jefferies Group LLC initiated coverage on shares of UROGEN PHARMA in a report on Tuesday, May 30th. They issued a “buy” rating and a $27.00 target price on the stock. Oppenheimer Holdings, Inc. initiated coverage on shares of UROGEN PHARMA in a report on Tuesday, May 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Finally, Raymond James Financial, Inc. initiated coverage on shares of UROGEN PHARMA in a report on Tuesday, May 30th. They issued an “outperform” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.00.

Shares of UROGEN PHARMA (URGN) traded down 0.09% during trading on Thursday, hitting $32.69. The stock had a trading volume of 62,385 shares. The company’s market capitalization is $425.26 million. UROGEN PHARMA has a 1-year low of $13.01 and a 1-year high of $33.77. The firm has a 50-day moving average of $21.34 and a 200 day moving average of $18.90.

TRADEMARK VIOLATION WARNING: “UROGEN PHARMA (URGN) Rating Lowered to Sell at Zacks Investment Research” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/16/urogen-pharma-urgn-rating-lowered-to-sell-at-zacks-investment-research.html.

Several institutional investors have recently added to or reduced their stakes in URGN. FMR LLC bought a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $13,892,000. Hillhouse Capital Management Ltd. bought a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $6,363,000. Jennison Associates LLC bought a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $3,168,000. Wildcat Capital Management LLC bought a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $2,439,000. Finally, Menora Mivtachim Holdings LTD. bought a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $2,331,000. 36.06% of the stock is owned by hedge funds and other institutional investors.

About UROGEN PHARMA

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Receive News & Stock Ratings for UROGEN PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UROGEN PHARMA and related stocks with our FREE daily email newsletter.